These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 2645701)
1. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Simpson MA; Madras PN; Cornaby AJ; Etienne T; Dempsey RA; Clowes GH; Monaco AP Transplantation; 1989 Feb; 47(2):218-23. PubMed ID: 2645701 [TBL] [Abstract][Full Text] [Related]
2. Serum & urinary interleukin-2 levels as predictors in acute renal allograft rejection. Gupta RK; Jain M; Sharma RK Indian J Med Res; 2004 Jan; 119(1):24-7. PubMed ID: 14997990 [TBL] [Abstract][Full Text] [Related]
3. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. Casiraghi F; Ruggenenti P; Noris M; Locatelli G; Perico N; Perna A; Remuzzi G Transplantation; 1997 May; 63(10):1508-14. PubMed ID: 9175818 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477 [TBL] [Abstract][Full Text] [Related]
5. Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Yoshimura N; Oka T; Kahan BD Transplantation; 1991 Jan; 51(1):172-6. PubMed ID: 1987687 [TBL] [Abstract][Full Text] [Related]
6. A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Colvin RB; Preffer FI; Fuller TC; Brown MC; Ip SH; Kung PC; Cosimi AB Transplantation; 1989 Nov; 48(5):800-5. PubMed ID: 2815252 [TBL] [Abstract][Full Text] [Related]
7. Clinical graft evolution of lymphocytes, polymorphonuclear cells, and antigen expression in tubular renal cells in the urine sediment of 20 renal allograft recipients. Péfaur J; Triviño R; Navarrete C; Oberhauser E; Melys M; Morales I; Salinas P; Mocarquer A Transplant Proc; 2003 Nov; 35(7):2500-5. PubMed ID: 14611996 [TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptor (sIL-2R) levels in renal transplantation: comparison between clinical and laboratory analysis. Montagnino G; Tarantino A; Grignani S; Braga M; Ponticelli C Clin Transplant; 1995 Feb; 9(1):25-30. PubMed ID: 7742579 [TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-2 and soluble interleukin-2 receptor in renal transplant recipients. Lee PH; Chung YC; Hu RH; Huang MT; Chao SH; Lee CJ; Lee CS J Formos Med Assoc; 1992 Sep; 91(9):844-8. PubMed ID: 1363382 [TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627 [TBL] [Abstract][Full Text] [Related]
15. The utility of urine cytology in the diagnosis of allograft rejection after combined pancreas-kidney transplantation. Radio SJ; Stratta RJ; Taylor RJ; Linder J Transplantation; 1993 Mar; 55(3):509-16. PubMed ID: 8384382 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic assessment of the in vivo cyclosporine effect on interleukin-2 production by lymphocytes in kidney transplant recipients. Yoshimura N; Kahan BD Transplantation; 1985 Dec; 40(6):661-6. PubMed ID: 3934806 [TBL] [Abstract][Full Text] [Related]